You are here: Industry Insights > Kintor

News List

Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients prnasia
March 11, 2021
Kintor Pharmaceutical Limited announced top-line results from its investigator-initiated Brazil trial evaluating the efficacy of Proxalutamide relative to standard of care as assessed by the COVID-19 ordinal scale.
Kintor's GT20029 IND for PROTAC AR Degrader Was Accepted by NMPA prnasia
February 02, 2021
Kintor Pharmaceutical Limited is pleased to announce that the investigational new drug application of GT20029 for androgenetic alopecia and acne vulgaris indications has been accepted by the National Medical Products Administration of China.
Clinical Trial of Proxalutamide's Trial of Hospitalized Covid-19 Patients Was Approved in Brazil prnasia
January 29, 2021
Kintor Pharmaceutical Limited is pleased to announce that the clinical trial of Proxalutamide's treatment of hospitalized COVID-19 patients was approved by the Institutional Review Board of Brazil.
Kintor's Proxalutamide (GT0918) COVID-19 Clinical Trial Shows Positive Preliminary Results in Treatment of Female Patients prnasia
January 11, 2021
Kintor Pharmaceutical Limited is pleased to update the preliminary analysis of the clinical trial of Proxalutamide for the treatment of COVID-19 patients.
CMAB and Kintor Enter Mfg. Tie-up contractpharma
August 26, 2019
Collaboration aims to develop and manufacture the ALK-1 monoclonal antibody.
CMAB, Kintor announce comprehensive collaboration biospectrumasia
August 22, 2019
China based CMAB Biopharma Inc. (CMAB), a pure-play CDMO business in biologics and Suzhou Kintor Pharmaceuticals, Inc. (Kintor), an innovative biopharmaceutical enterprise, have announced a comprehensive strategic cooperation agreement for the development

Previous page 1 2 Next page